Sri Lanka Cancer Registry 15th Publication

CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2013

Other all 30.5% Female 8370 CR 47.9 Total 9112 80.6 52.1 17482 90.4 86.7 100.0 88.7 83.7 Oesophagus 89.2 Bladde Cancer Incidence in >, 3.5% 10854 12253 0.001 3.9% NATIONAL CANCER CONTROL PROGRA Æ Lymphoma MINISTRY OF HEALTH 5.0% Larynx Prostate 5.1% Other and unspecified CR ASR 6.5% 5.7%

National Cancer Incidence and Mortality Data

Sri Lanka 2013



National Cancer Control Programme

Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka 15th Publication – National Cancer Incidence and Mortality Data Sri Lanka: 2013

Published date – March 2021

Acknowledgements

National Advisory Committee on Prevention & Control of Cancers

World Health Organization- Country Office, Sri Lanka

Cancer Care Association - Sri Lanka

Compiled by

Strategic Information and Management (SIM) Unit National Cancer Control Programme Sri Lanka

Published by



National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka

Contact No +94 112368627, Fax +94 112368627 Email- <u>nccpsl@yahoo.com</u> Web – <u>www.nccp.health.gov.lk</u>

facebook

National Cancer Control Programme, Sri Lanka

Executive Summary

'Cancer Incidence Data Sri Lanka – 2013' is the 15th volume of the series of publication on cancer surveillance data of Sri Lanka. This is the output report of National Cancer Registry / Sri Lanka Cancer Registry (SLCR) based on newly reported cancers in the year 2013. The Cancer Incidence Data is collected through the government cancer treatment centres, pathology laboratories, Oral and Maxillo-Facial (OMF) surgery units in the country. As a new initiative of cancer surveillance from year 2012, the Population Based Cancer Registry (PBCR) of Colombo district was also commenced. The additional data sources considered for the Population Based Cancer Registry initiative in Colombo district were also incorporated to the national cancer registry database. All the data were entered into the CanReg 5 database. When processing the data, quality checks were conducted and duplicate entries were eliminated. Analysis was conducted using Can Reg 5 software and SPSS software.

In the year 2013, a total of 23,531 new patients with cancers were reported, giving a crude incidence rate (CR) of 114.3 per 100,000. Crude incidence rates of males and females were 114.0 /100,000 (n=11,364) and 114.6/100,000 (n=12,167). The highest 5-year age specific incidence rates were reported among males of 70-74 age group (740.4 /100,000) and females of 70-74 (442.0/100,000) age group. When age standardized rates (ASR) were considered, the overall ASR was 100.7 /100,000 and the ASR for males and females were 106.3/100,000 and 97.4/100,000 respectively. The absolute numbers, crude rates and age standardized rates were increased in relation to the similar figures of year 2012.

Lip, tongue & mouth (n=1755, ASR=16.1/100,000), Lung (n=1081, ASR = 10.2/100,000), Colon & rectum (n=835, CR=8.4/100,000) and Oesophagus (n=828, CR = 8.3/100,000) were the highest incident cancer among males. When the top ten cancers among males were considered the first four positions had remained same as the previous year.

Breast (n=3234, ASR =25.7/100,000), thyroid (n=1175, ASR = 9.8/100,000), cervix (n=895, ASR =7.0 /100,000), colorectal (n=865, CR=6.7/100,000) were the highest incident cancers among females. Thyroid cancer became the second commonest cancer among females while cervical cancer remained at third position. Compared with the 2012 data among females, colorectal cancer had come up in the list to 4th position pushing ovary cancer to 5th position.

Cumulative risk of developing cancer between the age group of 0-74 for males and females were 12.86% & 11.07% respectively. When sites of cancers were considered, highest cumulative risk of developing cancer between the age group of 0-74 males were reported for cancer of trachea, bronchus & lung (1.36%), mouth cancer (1.22%) and esophagus (0.97%). Similarly, highest cumulative risk of developing cancer between the age group of 0-74 females were reported for breast cancer (2.93%), thyroid cancer (0.88%) and cervical cancer (0.84%).

Among children and adolescents, the most common cancer was Leukemias, myeloproliferative diseases and myelodysplastic diseases(n=207), while lymphomas(n=88), CNS neoplasms(n=59), neuroblastomas and other peripheral nervous cell tumors (21) had positioned next in list respectively.

Mortality data received through Department of Census & Statistics and Annual Health Bulletin. A total of 7,166 (Crude death rate 71.9/100,000) and 5,788 (Crude death rate 54.5/100,000) cancer related deaths were reported among males and females respectively in the year 2013. Age specific death rates among females were lower than males and death rates were increasing over the advanced age. Malignant neoplasm of trachea, bronchus and lung is the leading cause of death among males and cancer of the breast is the leading cause of death among females.

Table of Contents

	Page No
Acknowledgements	3
Executive Summary	4
Table of Contents	6
List of Tables	7
List of Figures	8
Introduction	9
Methodology	10
Cancer Incidence Data of Sri Lanka – Tables and Figures	16
Mortality of Cancers	40

List of Tables

Table	No Description	Page No
Section	1 – Cancer Incidence Data of Sri Lanka, 2013	
01	Population of Sri Lanka: sex distribution 2006 – 2013	16
02	Cancer incidence by sex in Sri Lanka, 2006 – 2013	17
03	Cancer incidence by 5-year age groups and sex in Sri Lanka, 2013	19
04	Leading cancer sites by sex in Sri Lanka, 2013	20
05	Cancer cases by 5-year age group among Males in Sri Lanka, 2013	22
06	Cancer cases by 5-year age group among Females in Sri Lanka, 2013	26
07	Number of incidence cancers by five-year age group and	
	site among Males in Sri Lanka, 2013	30
08	Number of incidence cancers by five-year age group and	
	site among Females in Sri Lanka, 2013	31
09	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Males in Sri Lanka, 2013	32
10	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Females in Sri Lanka, 2013	33
11	Childhood & Adolescent (0-19) Cancer Incidence Data according to International Childhood Cancer Classification (ICCC-3)	34
Section	2 – Cancer Mortality Data of Sri Lanka 2013	
12	Deaths due to cancers at the government hospitals in Sri Lanka, 2005-2013	40
13	Deaths due to cancers out of all registered deaths in hospitals & field in Sri Lanka, 2005 – 2013	40
14	Deaths due to cancers out of all registered deaths by sex in hospitals & field in Sri Lanka, 2005 – 2013	41
15	Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2013	42
16	Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2013	42

List of Figures

Table	e No Description	Page No
Section	n 1 – Cancer Incidence Data of Sri Lanka 2013	
01	General population in Sri Lanka by 5-year age groups in year 2013 (Population Pyramid)	16
02	Crude Cancer Incidence Rates in Sri Lanka, 2006 – 2013	18
03	Age Standardized Cancer Incidence Rates in Sri Lanka, 2006 – 2013	18
04	Cancer Incidence Rates in Sri Lanka – 2013	19
05	Age Specific Cancer Incidence rates in Sri Lanka – 2013	20
06	Proportion of leading cancers in Males in Sri Lanka – 2013	21
07	Proportion of leading cancers in Females in Sri Lanka – 2013	21
Section	n 2 – Cancer Mortality Data of Sri Lanka 2013	
08	Age Standardized mortality rates due to cancer in Sri Lanka, 2001 – 2013	41

Cancer Incidence & Mortality Data Sri Lanka – 2013

1. Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates surveillance of cancers in Sri Lanka with the active participation of other stakeholders for cancer surveillance including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) units, professional colleges, WHO country office etc. The process of surveillance of cancers is technically guided by the International Agency for Research on Cancer (IARC) of WHO and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical guidance is received from Department of Epidemiology, Bis statistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as a publication named 'Cancer Incidence Data Sri Lanka'. Up to now 14 volumes have been published as shown in Table 1. This publication is the 15th volume of Cancer Incidence Data Sri Lanka.

Year of			Publi	cation				
cancer incidence data	Cancer Treatment Centres	Pathology laboratories	OMF units	Medical Record Rooms	Death Registrars	Total no. of centres	Volume	Year publishe d
1985	3	_	_	_	_	3	1	1990
1986	3	_	_	_	_	3	2	1991
1987	3	_	_	_	_	3	3	1993
1990	3	_	_	_	_	3	4	1996
1995	3	_	_	_	_	3	5	2002
2000	4	_	_	_	_	4	6	2006
2001-2005	5	_	_	_	_	5	7	2009
2006	6	_	4	_	_	10	8	2012
2007	6	_	4	_	_	10	9	2013
2008	7	16	17	_	_	40	10	2014
2009	9	15	17	_	_	41	11	2015
2010	9	13	17	_	_	39	12	2016
2011	9	13	12	-	-	34	13	2018
2012	9	37	15	9	40	110	14	2020

Table (i) Summary details of previous publications of 'Cancer Incidence Data Sri Lanka'

2. Methodology Cancer Incidence Data

The methodology of surveillance for cancer incidence data includes (i) collection of cancer incidence data from the point of diagnosis /from the point of treatment, (ii) coding of cancer incidence data, (iii) entering of cancer incidence data to the database, (iv) duplicate checking & verification of data, (v) analysis of data and (vi) dissemination of information through the publication of 'Cancer Incidence Data Sri Lanka' and other modes.

The methodology of each step of cancer surveillance is described below.

2.1.1 Collection of cancer incidence data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) units throughout the country. In addition, the

2.1.1 Newly registered cancer patients at the cancer treatment centres

In the year 2013, there were 9 government cancer treatment centres involved in data collection (table i). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Data were extracted by the medical officers, nursing officers and development officers attached to the cancer treatment centres, trained pre-intern medical graduates temporarily recruited through WHO Biennium funds and by the cancer registry staff of NCCP.

Category of hospital	Name of the hospital							
National Hospitals	Apeksha Hospital - Maharagama (National Cancer							
	Institute)							
Teaching Hospitals	Kandy, Karapitiya, Anuradhapura, Batticaloa							
Provincial General Hospitals	Badulla, Kurunegala, Rathnapura							
Base Hospital	Telippalai (Jaffna)							

Table (ii) Distribution of government cancer treatment centres in year 2013

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 38 Histopathology laboratories (12,299 diagnosed patients), 6 Haematology laboratories (378 diagnosed patients) and one oral pathology laboratory (429 diagnosed patients) have passively sent relevant data for the year 2013 (table ii).

Table (iii) Distribution of pathology laboratories which sent details of newly diagnosedcancer patients in year 2013

Category of	Type of Pathology laboratory										
hospital	Histopathology	Haematology	Oral Pathology								
National	National Hospital of Sri Lanka										
Hospital											
Teaching	De Soysa Hospital for Women, Castle										
Hospitals	Hospital for Women, Lady Ridgeway										
	Hospital, National Eye Hospital,										
	Colombo South,Colombo North,										
	National Hospital for Respiratory										
	Diseases-Welisara, .										
	Karapitiya,Kandy,Peradeniya,										
	Batticaloa										
Provincial	Kurunegala, Rathnapura, Badulla	Kurunegala									
General		,Badulla									
Hospitals											
District General	Avissawella,Gampaha,Negombo,	Kalutara,									
Hospitals	Kalutara,Nawalapitiya,Matale,	Hambanthota,									
	Monaragala ,Chilaw, Vavuniya	Chilaw									
		,Monaragala									
Base Hospital	Homagama, Mulleriyawa, Wathupitiwala,										
	Kethumathi,Balapitiya,										
	Tangalle,Embilipitiya,Balangoda,										
	Gampola,Karawanella										
University	Faculty of Medicine – Colombo,		Faculty of								
Units	Ruhuna		Dental								
			Sciences –								
			Peradeniya								
Other	MRI										
Institutions											
Private sector	-										

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

Data on newly confirmed cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received annually through the Annual Notification Form of Oral Cancer (H -1294). A total of 15 OMF units have sent relevant data for year 2013 (table iii).

Table (iv) Distribution of OMF	Units	which	sent	details	of	newly	diagnosed	cancer
patients in year 2013								

Category of hospital	Name of the hospital
National Hospital	Dental Institute Colombo
Teaching Hospitals	Colombo South, Colombo North, Karapitiya, Kandy
Provincial General Hospitals	Badulla, Kurunegala, Rathnapura
District General Hospitals	Gampaha, Kalutara, Chilaw, Kegalle, Polonnaruwa
Base Hospital	Kuliyapitiya, Panadura
University Units	

2.1.4 Incorporation of additional cancer incidence data collected for the Population Based Cancer Registry – Colombo district

Two additional data sources were identified for capturing further cancer incidence data from Colombo district when commencing the Population Based Cancer Registry and those data sources were also incorporated as data generating centres for national cancer registry.

Details from Medical Record Departments of Hospitals situated in Colombo district & adjacent districts

The information on cancer patients treated at the secondary and tertiary care hospitals in the government sector, private sector and armed services in the Colombo district and selected hospitals in the adjacent districts were collected through the 'Cancer Return Form -2' (H-1291). A total of 25 Medical Record Departments have sent the details in year 2013 (table iv). Out

Table (v) Distribution of Medical Record Departments of Hospitals which sent details ofnewly diagnosed cancer patients in year 2013

Category of hospital	Name of the hospital						
National Hospital	National hospital, Dental Institute Colombo, Eye hospital						
	LRH, DMH, CSHW						
Teaching Hospitals	Colombo South, Colombo North, Chest Hospital ,Sri						
	Jayawardanapura						
District General Hospitals	Avissawella, Gampaha ,Mulleriyawa						
Base Hospital	Panadura, Horana						
Private Sector hospitals	Asiri Central, Asiri Medical, Asiri Surgical, Durdans, Lanka						
	Hospitals, Delmon, Oasis						
Armed Services hospitals	Army hospital, Navy hospital, Police hospital						

Details from Divisional Death Registrars of the Colombo district

Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form -3. A total of 40 divisional death registrars have sent relevant details for the year 2013.

2.2 Coding of cancer incidence data

According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer. The cancer registry staff of the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP. The process of data entering was closely supervised by the cancer registry staff and was regularly involved in refresher training to the data entry operators to ensure accuracy and quality of data.

2.4 Duplicate checking & verification of data

While entering and confirming the data to the CanReg5 data base, duplicate checking was conducted using 'Person search' option of the CanReg 5 data base. In addition to the duplicate checking done through CanReg 5, further duplicate checking had to be conducted during the data verification stage as well to identify all possible duplicates.

The additional methods used were;

i. Use of Linkpro software

ii. Use of Excel software – Sorted according to the descending or ascending order of selected variables

After removing possible duplicates, consistency checking and verification was conducted using 'IARCcrg' tool & MS Excel.

Mismatches according to;

Age/Incidence and birthdates Age /Site /Histology Site /Histology Sex/Site Sex/Histology Behaviour /Site Behaviour / Histology Grade /Histology Basis of Diagnosis /Histology were corrected.

After these procedures, preliminary analysis was conducted using CanReg 5 & SPSS to detect further mismatches. Data sources up to the patient clinic files were rechecked in the instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of cancer incidence data

Analysis section of the CanReg 5 package, SPSS and MS Excel software were used to analyze cancer incidence data. The standard cancer registry tables described at the Cancer incidence in 5 continents (CI 5) were generated through CanReg 5 database.

The estimated population data for year 2013 for calculation cancer incidence & mortality data was received from the Department of Census & Statistics.

Table (vi) Estimated population for year 2013

	Estimated Population	
Male	9,965,956	
Female	10,619,085	
Total	20,585,041	

Source – Department of Census & Statistics of Sri Lanka

Cancer Mortality Data

Cancer mortality data were received through two sources at national level.

(i) Hospital Indoor Morbidity Mortality Return of Medical Statistics unit of Ministry of Health

(ii) Cause specific death data published by the Department of Census & Statistics.

Based on the available data further analysis was conducted.

Cancer Incidence Data of Sri Lanka




Figure 1 : General population in Sri Lanka by 5-year age groups (Population Pyramid)

		Year									
	2006	2007	2008	2009	2010	2011	2012	2013			
Male ('000)	9889	9956	10060	10148	10249	10381	9856	9965			
Female ('000)	9969	10083	10186	10302	10404	10511	10502	10619			
Sex Ratio	99.2	98.7	98.8	98.5	98.5	98.8	93.8	93.8			

Table 1 : Population of Sri Lanka: sex distribution 2006 – 2013

Sex	Number	%	CR	ASR
Male	6205	44.1	62.7	69.2
Female	7875	55.9	79.0	79.5
Total	14080		70.9	74.2
Male	6,356	46.6	63.8	70.9
Female	7,279	53.4	72.2	72.8
Total	13,635		68.0	71.6
Male	7695	46.6	76.5	85.5
Female	8,816	53.4	86.6	88.0
Total	16511		81.6	86.4
Male	7858	46.5	77.4	86.4
Female	9030	53.5	87.7	89.1
Total	16888		82.6	87.5
Male	7,993	4701	78.0	87.4
Female	8,970	52.9	86.2	87.7
Total	16,963		82.1	87.3
Male	8370	47.9	80.6	90.4
Female	9,112	52.1	86.7	88.7
Total	17482		83.7	89.2
Male	11363	49.1	115.3	107.8
Female	11773	50.9	112.1	95.5
Total	23136		113.6	100.1
Male	11364	48.3	114.0	106.3
Female	12167	51.7	114.6	97.4
Total	23531		114.3	100.7
	Male Female Total Female Female Female Female Female Female <td>Male 6205 Female 7875 Total 14080 Male 6,356 Female 7,279 Total 13,635 Male 7695 Female 8,816 Total 16511 Male 7858 Female 9030 Total 16888 Female 9,930 Total 16888 Female 9,930 Total 16888 Female 9,930 Total 16888 Male 7,993 Female 8,970 Total 16,963 Male 8370 Female 9,112 Total 17482 Male 11363 Female 11773 Total 23136 Male 11364 Female 12167</td> <td>Male 6205 44.1 Female 7875 55.9 Total 14080 14080 Male 6,356 46.6 Female 7,279 53.4 Total 13,635 13 Total 13,635 46.6 Female 7,279 53.4 Total 13,635 46.6 Female 8,816 53.4 Total 16511 16 Male 7858 46.5 Female 9030 53.5 Total 16888 10 Male 7,993 4701 Female 8,970 52.9 Total 16,963 10 Female 9,112 52.1 Total 17482 10 Female 11363 49.1 Female 11773 50.9 Total 13136 11 Male 11364 48.3 Female 11364</td> <td>Male 6205 44.1 62.7 Female 7875 55.9 79.0 Total 14080 70.9 Male 6,356 46.6 63.8 Female 7,279 53.4 72.2 Total 13,635 68.0 Male 7695 46.6 76.5 Female 7695 46.6 76.5 Female 8,816 53.4 86.6 Total 16511 81.6 Male 7858 46.5 77.4 Female 9030 53.5 87.7 Total 16888 82.6 82.6 Male 7,993 4701 78.0 Female 8,970 52.9 86.2 Total 16,963 82.1 83.7 Male 8370 47.9 80.6 Female 9,112 52.1 86.7 Total 16,963 49.1 115.3 Female</td>	Male 6205 Female 7875 Total 14080 Male 6,356 Female 7,279 Total 13,635 Male 7695 Female 8,816 Total 16511 Male 7858 Female 9030 Total 16888 Female 9,930 Total 16888 Female 9,930 Total 16888 Female 9,930 Total 16888 Male 7,993 Female 8,970 Total 16,963 Male 8370 Female 9,112 Total 17482 Male 11363 Female 11773 Total 23136 Male 11364 Female 12167	Male 6205 44.1 Female 7875 55.9 Total 14080 14080 Male 6,356 46.6 Female 7,279 53.4 Total 13,635 13 Total 13,635 46.6 Female 7,279 53.4 Total 13,635 46.6 Female 8,816 53.4 Total 16511 16 Male 7858 46.5 Female 9030 53.5 Total 16888 10 Male 7,993 4701 Female 8,970 52.9 Total 16,963 10 Female 9,112 52.1 Total 17482 10 Female 11363 49.1 Female 11773 50.9 Total 13136 11 Male 11364 48.3 Female 11364	Male 6205 44.1 62.7 Female 7875 55.9 79.0 Total 14080 70.9 Male 6,356 46.6 63.8 Female 7,279 53.4 72.2 Total 13,635 68.0 Male 7695 46.6 76.5 Female 7695 46.6 76.5 Female 8,816 53.4 86.6 Total 16511 81.6 Male 7858 46.5 77.4 Female 9030 53.5 87.7 Total 16888 82.6 82.6 Male 7,993 4701 78.0 Female 8,970 52.9 86.2 Total 16,963 82.1 83.7 Male 8370 47.9 80.6 Female 9,112 52.1 86.7 Total 16,963 49.1 115.3 Female

Table 2 Cancer Incidence by sex, 2006-2013




Figure 2 : Crude Cancer Incidence Rates-Sri Lanka, 2006 – 2013




Figure 3 : Age Standardized Cancer Incidence Rates- Sri Lanka, 2006 - 2013




Figure 4 : Cancer Incidence Rates in Sri Lanka - 2013

A = 0		Male			Female			Total	
Age Group	Cases	Populati- on	Incidence	Cases	Populati- on	Incidence	Cases	Populati- on	Incidence
Unknown	22			27			49		
00-04	115	889230	12.9	102	874485	11.7	217	1763715	12.3
05-09	55	892056	6.2	56	875418	6.4	111	1767474	6.3
10-14	69	838363	8.2	61	820101	7.4	130	1658464	7.8
15-19	102	829051	12.3	109	833562	13.1	211	1662613	12.7
20-24	91	750463	12.1	167	799285	20.9	258	1549748	16.6
25-29	114	751731	15.2	229	818343	28.0	343	1570074	21.8
30-34	215	805683	26.7	440	851903	51.6	655	1657586	39.5
35-39	253	693603	36.5	603	731009	82.5	856	1424612	60.1
40-44	461	668902	68.9	848	705248	120.2	1309	1374150	95.3
45-49	780	624984	124.8	1167	675054	172.9	1947	1300038	149.8
50-54	1250	587732	212.7	1459	645191	226.1	2709	1232922	219.7
55-59	1509	506403	298.0	1606	569525	282.0	3115	1075928	289.5
60-64	1822	430082	423.6	1684	497822	338.3	3506	927904	377.8
65-69	1632	286828	569.0	1431	353263	405.1	3063	640091.2	478.5
70-74	1361	183810	740.4	1030	233023	442.0	2391	416832.9	573.6
75+	1514	227035	666.9	1148	335854	341.8	2662	562889	472.9
Total	11365	9965956	114.0	12167	10619085	114.6	23532	20585041	114.3

Table 3Cancer incidence by 5 year age groups & sex - 2013

	Male					Fen	nale		
ICD 10	Site	No	CR	ASR	ICD 10	Site	No	CR	ASR
C00-C06	Lip, tongue and mouth	1755	17.6	16.1	C50	Breast	3234	30.5	25.7
C33-C34	Trachea, bronchus and lung	1081	10.9	10.2	C73	Thyroid	1175	11.1	9.8
C18-C20	Colon and rectum	835	8.4	7.8	C53	Cervix Uteri	895	8.4	7.0
C15	Oesophagus	828	8.3	7.6	C18-C20	Colon and rectum	865	8.1	6.7
C61	Prostate	717	7.2	7.0	C56	Ovary	783	7.4	6.3
C09-C14	Pharynx	634	6.4	5.9	C15	Oesophagus	676	6.4	5.2
C32	Larynx	613	6.2	5.7	C54- C55	Uterus	668	6.3	5.2
C81-C86, C96	Lymphoma	537	5.4	5.1	C00-C06	Lip, tongue and mouth	476	4.5	3.7
C67	Bladder	434	4.4	4.1	C81- C86, C96	Lymphoma	382	3.6	3.2
C91-C95	Leukaemia	414	4.2	4.1	C91-C95	Leukaemia	334	3.1	3.0
All	sites	11364	114.0	106.3		All Sites	12167	114.6	97.4

 Table 4 : Leading cancer sites by sex - 2013




Figure 5 - Age Specific Cancer Incidence rates -2013




Figure 6 - Proportion of leading cancers in Males in Sri Lanka - 2013




Figure 7 - Proportion of leading cancers in Females in Sri Lanka - 2013

Table 05: Cancer cases by 5 year age group among males in Sri Lanka – Male 2013

											Age	e Group							
ICD 1	10 code and site	NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C00	Lip	0	0	0	0	0	0	0	1	2	0	4	5	11	12	7	4	10	56
C01	Base of tongue	0	0	0	0	0	0	0	0	5	8	11	34	29	20	26	9	14	156
C02	Other and unspecified parts of tongue	0	0	0	0	0	0	3	6	9	28	63	68	89	67	44	34	38	449
C03	Gum	0	0	0	0	1	0	1	0	1	4	8	15	17	24	10	19	23	123
C04	Floor of mouth	0	0	0	0	0	0	1	2	1	9	15	28	17	19	23	12	14	141
C05	Palate	0	0	0	0	0	0	0	3	0	14	30	29	35	28	24	13	18	194
C06	Unspecified part of mouth	1	0	0	0	0	1	2	6	12	24	63	74	105	83	96	77	92	636
C07	Parotid gland	0	1	0	0	0	2	0	4	6	3	3	8	5	9	4	7	5	57
C08	Unspecified major salivary gland	0	0	0	0	0	0	0	2	1	1	1	5	3	1	1	1	4	20
C09	Tonsil	0	0	0	0	0	0	0	0	2	12	22	22	30	24	28	17	11	168
C10	Other oropharynx	0	0	0	0	0	0	0	1	1	7	9	18	20	24	12	14	3	109
C11	Nasopharynx	0	0	0	0	5	1	0	3	1	0	2	6	1	9	3	6	1	38
C12	Piriform sinus	0	0	0	0	0	0	0	0	0	5	17	27	24	34	27	20	17	171
C13	Hypopharynx	0	0	0	0	0	0	0	0	0	2	2	7	6	10	10	6	6	49
C14	Lip oral cavity and pharynx- unspcified	1	0	0	0	0	0	0	0	2	2	6	23	13	12	16	10	14	99
C15	Oesophagus	1	0	0	0	0	0	0	5	3	37	44	118	149	155	116	100	100	828
C16	Stomach	1	0	0	0	0	0	2	0	6	17	29	51	72	71	56	39	47	391
C17	small intestine	0	0	0	0	0	1	0	0	1	1	1	6	8	10	3	4	4	39
C18	Colon	1	0	0	0	0	1	2	10	17	22	22	45	45	53	58	43	48	367
C19	Recto sigmoid junction	0	0	0	0	0	0	0	1	1	3	5	4	4	12	8	11	12	61
C20	Rectum	1	0	0	0	0	0	5	1	8	17	25	26	56	70	52	66	80	407
C21	Anus and anal canal	0	0	0	0	0	0	1	1	0	1	1	2	7	3	12	3	4	35
C22	Liver and intra hepatic bile duct	1	5	0	1	1	0	0	0	2	4	4	15	19	42	37	41	37	209
C23	Gallbladder	1	0	0	0	0	0	0	0	0	1	1	1	2	6	3	2	1	18
C24	Unspcified part of billiary tract	0	0	0	0	0	0	0	0	0	5	6	10	8	7	5	6	6	53
C25	Pancreas	0	0	0	0	0	2	0	0	0	6	9	12	8	12	9	5	11	74
C26	Other and ill- defined digestive organs	2	0	0	0	0	0	0	1	0	0	0	0	0	4	3	4	1	15
C30	Nasal cavity and middle ear	1	3	0	0	2	0	0	2	2	2	1	2	5	9	1	5	2	37
C31	Accessory sinuses	0	0	0	0	0	0	0	0	2	1	0	3	5	5	3	4	5	28
C32	Larynx	1	0	0	0	0	0	0	4	4	15	54	76	96	118	110	65	70	613
C33	Trachea	0	0	0	0	0	0	0	0	0	0	2	2	0	2	2	0	0	8

											Age	Group							
ICD	10 code and site	NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C34	Bronchus and lung	2	0	0	0	0	0	3	6	8	19	52	108	153	229	212	150	132	1074
C37	Other thoracic organs	0	0	0	0	0	1	2	2	2	2	2	1	0	5	4	1	0	22
C38	Heart, mediastinum and pleura	0	0	1	0	0	2	7	3	2	3	2	0	3	4	0	4	0	31
C39	Other and ill- defined sites of intrathoracic organs	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
C40	Bone and articular cartilage of	0	2	2	5	10	5	4	5	1	0	1	0	0	1	1	0	0	37
C41	limbs Bone and articular cartilage of	0	0	1	2	2	4	2	4	3	0	1	3	1	0	0	0	3	26
C43	limbs Melanoma of skin	0	0	0	0	1	2	0	1	1	3	0	6	3	5	8	8	10	48
C44	Other skin	1	0	0	1	0	3	2	2	6	17	18	27	42	40	34	24	37	254
C45	Mesothelioma	0	0	0	0	1	0	0	1	0	0	0	0	1	1	0	1	1	6
C47	Peripheral nerves and autonomic nervous system	0	0	0	0	1	1	0	1	0	2	1	1	2	0	1	0	2	12
C48	Retroperitoneu m and peritoneum	0	0	0	0	0	0	0	0	1	0	2	2	2	2	1	0	1	11
C49	Other connective and soft tissue	0	6	1	6	3	1	5	6	3	9	10	5	13	14	7	10	10	119
C50	Breast	1	0	0	0	0	0	1	2	3	2	6	7	11	15	7	0	9	64
C60	Penis	0	0	0	0	0	0	0	1	3	4	6	9	14	11	12	14	24	98
C61	Prostate	1	1	0	0	0	0	0	0	0	3	4	20	27	102	148	184	227	717
C62	Testis	0	1	2	1	1	4	8	13	5	4	7	2	1	2	1	0	2	54
C63	Other and unspecified male genital organs	0	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	4
C64	Kidney	0	1 0	2	1	2	0	0	7	8	6	20	30	26	40	29	20	28	229
C65	Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	0	0	5
C67	Bladder	1	0	0	1	2	0	2	4	1	12	12	27	41	88	85	75	83	434
C68	Other and unspcified part of urinary organs	0	0	0	0	0	0	0	0	0	0	1	0	0	1	6	0	2	10
C69	Eye	0	8	1	0	0	0	0	1	0	0	0	1	2	3	3	0	1	20
C70	Meninges	0	0	0	0	0	0	0	1	1	0	1	0	2	0	0	0	0	5
C71	Brain	0	6	5	6	5	3	3	14	19	13	15	19	17	21	13	6	6	171
C72	Other parts of central nervous system	0	1	0	1	1	0	0	1	3	2	0	1	0	0	0	0	0	10
C73	Thyroid gland	0	1	0	4	1	9	1	27	35	29	17	25	31	25	17	13	13	265

											4.00	Group							
ICD I	10 code and site		4	9	4	6	4	6	4	0		Group	3	۲	4	0	4		P
		NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	62-69	70-74	75+	Total
								8											
C74	Adrenal gland	0	8	1	0	0	0	0	1	1	1	1	1	0	2	1	1	1	19
C75	Other endocrine glands	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0	0	0	3
C76	Other and ill defined site Unknown primary	1	4	1	0	0	0	0	1	2	1	2	3	6	7	9	4	9	50
C81	Hodgkin disease	3	1	1	0	2	1	3	9	11	31	67	100	96	111	112	88	96	732
C82	Follicular(nodul ar) non- Hodgkin lymphoma	0	1	1	3	8	1 2	5	4	9	6	8	6	7	5	3	3	0	81
C83	Diffuse non- Hodgkin lymphoma	0	0	0	0	1	1	1	1	3	1	2	3	3	7	1	0	4	28
C84	Peripheral and cutaneous T- cell lymphoma	0	5	6	4	9	1	6	2	3	2	7	5	12	10	6	8	14	100
C85	Other and unspecified types of non- Hodgkin lymphoma	0	0	0	0	1	0	0	1	1	0	0	3	3	2	5	4	1	21
C86	Other and unspecified types of non- Hodgkin lymphoma	0	3	2	3	8	1 0	5	10	9	13	17	39	37	39	33	29	39	296
C88	Immunoprolifer itive diseases Multiple	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	3
C90	myeloma and malignant plasma cell neoplasm	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	3
C91	lymphoid leukaemia	0	0	0	0	0	0	1	2	2	4	15	20	23	38	25	33	29	192
C92	Myeloid leukaemia	0	3	2	2	17	9	1	10	4	3	6	9	9	6	5	10	8	186
	Monocytic		6	1	3			0											
C93	Ieukaemia	0	2	2	5	13	3	7	17	10	15	13	17	21	22	21	13	12	193
C94	leukaemia of specified cell type	0	2	2	1	2	0	0	0	0	1	1	1	2	1	2	3	0	18
C95	Leukaemia of unspecified cell type Other	0	1	1	0	0	0	0	0	0	0	0	0	1	1	1	2	0	7
C96	neoplasms of lymphoid, haematopoeitic and related tissue	0	1	0	0	1	0	0	2	0	0	1	1	0	0	1	2	1	10
C97	Other leukaemia of specified cell typeB	0	5	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	8
D45	Polycythemia vera	0	0	0	0	0	0	0	0	1	1	0	0	2	0	2	1	0	7
D46	Myelodysplasti c syndromes	0	0	1	0	0	1	0	0	1	1	0	2	3	4	3	2	9	27
D47	Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4

and re tissue

										Age	Group							
ICD 10 code and site	NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
Total	22	115	55	69	102	16	114	215	253	461	780	1250	1509	1822	1632	1361	1514	11365

Table 06: Cancer cases by 5 year age group among females in Sri Lanka – Female 2013

										A	ge Grou	ւթ								
10	CD 10 code and site	NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+		Total
C00	Lip		0	0	0	0	0	0	0	0	1	1	1	2	4	3	1	4	0	17
C01	Base of tongue		0	0	0	0	0	0	0	0	0	0	0	3	6	3	7	2	0	21
C02	Other and unspecified parts of tongue		0	0	0	0	1	0	0	1	6	12	13	20	20	13	17	1 3	0	11 6
C03	Gum		0	0	0	0	0	0	0	0	1	1	1	3	7	5	5	1	0	36
C04	Floor of mouth		0	0	0	0	0	0	1	0	1	1	0	0	4	3	3	3 0	0	13
C05	Palate		0	0	0	1	0	1	0	0	3	1	2	2	2	7	5	1	0	34
C06	Other and unspecified parts of mouth		0	0	0	0	0	1	4	5	1	6	22	24	46	32	35	0 5 4	0	23 9
C07	Parotid gland		0	0	2	1	3	2	3	2	0	3	2	4	3	4	3	4	0	41
C08	Other and unspecified major salivary gland		0	0	0	0	0	0	3	0	0	1	2	1	3	2	1	1	0	14
C09	Tonsil		0	0	0	0	0	0	1	0	0	1	2	1	4	4	1	2	0	16
C10	Oropharynx		0	0	0	0	0	0	0	0	0	3	3	1	3	0	2	2	0	14
C11	Nasopharynx		0	0	0	3	1	0	0	1	1	1	1	1	1	2	1	2	0	15
C12	Pyriform sinus		0	0	0	0	0	0	0	0	1	1	1	1	5	3	2	4	0	18
C13	Hypopharynx		0	0	0	0	0	0	1	0	0	3	2	7	7	2	3	4	0	29
C14	Other and ill-defined sites		0	0	0	0	0	0	0	0	1	0	1	5	3	1	4	5	0	20
C15	Oesophagus		0	0	0	0	0	1	4	1	7	24	59	95	12 3	12 1	99	1 3	0	67 6
C16	Stomach		0	0	1	0	1	1	1	0	8	11	16	23	28	21	23	2 1	0	15
C17	Small intestine		0	0	0	0	1	1	1	0	3	3	2	3	5	7	2	9 3	0	3 31
C18	Colon		0	0	0	0	1	0	1	1	3	39	58	57	58	65	50	4	2	44
C19	Rectosigmoid junction		0	0	0	0	0	0	2 1	7 2	4 3	4	9	6	8	8	10	7 6	0	0 57
C20	Rectum		0	0	0	0	0	3	9	9	1 8	27	35	54	63	59	36	5 4	1	36 8

										A	ge Grou	ıp								
I	CD 10 code and site	NK	00-04	02-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+		Total
C21	Anus and anal canal		0	0	0	0	0	1	0	2	2	3	5	7	2	7	4	4	0	37
C22	Liver and intrahepatic bile duct		8	1	0	0	0	0	1	0	4	2	9	9	7	11	12	1 9	1	84
C23	Gallbladder		0	0	0	0	0	0	0	1	1	2	9	3	4	3	6	5	0	34
C24	Other and unspecified parts of biliary tract		0	0	0	0	1	0	0	1	2	9	7	7	9	6	4	4	0	50
C25	Pancreas		0	0	0	1	0	1	1	2	7	9	10	12	12	14	3	5	0	77
C26	Other and ill-defined digestive organs		0	0	0	0	0	1	0	0	1	0	2	3	2	4	0	2	0	15
C30	Nasal cavity and middle ear		0	0	0	0	0	0	0	2	1	1	2	3	8	2	1	2	0	22
C31	Accessory sinuses		0	0	0	0	0	0	0	1	0	0	2	1	3	1	1	4	0	13
C32	Larynx		0	1	0	0	1	0	3	1	3	6	5	7	7	6	7	9	0	56
C33	Trachea		0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	3
C34	Bronchus and lung		0	0	0	1	0	1	7	1	1	29	35	42	52	59	40	3	1	32
C37	Thymus		0	0	0	0	0	1	1	5 1	4 2	1	3	1	4	2	0	1 1	0	7 17
C38	Heart, mediastinum and pleura		0	1	0	0	1	0	0	0	2	1	1	0	0	1	2	0	0	9
C40	Bone and articular cartilage of limbs		0	3	5	5	2	4	1	2	1	0	3	0	3	1	0	1	0	31
C41	Bone and articular cartilage of other and unspecified sites		2	2	2	3	3	4	0	5	0	1	3	1	1	1	1	1	1	31
C43	Melanoma of skin		0	0	0	0	0	0	0	2	3	2	5	4	3	3	8	2	0	32
C44	Other malignant neoplasms of skin		0	0	0	1	1	3	3	5	3	9	19	23	29	18	33	4	1	19
C45	Mesothelioma		0	0	0	0	0	0	0	1	0	0	0	2	3	2	1	4	0	2 10
C47	Peripheral nerves and autonomic nervous system		1	1	0	2	0	0	1	0	0	1	0	1	0	0	0	0	0	7
C48	Retroperitoneum and peritoneum		1	0	0	1	0	0	0	0	2	1	1	2	3	1	0	0	0	12
C49	Connective, subcutaneous and other soft tissue		3	4	3	6	2	2	6	6	1 0	8	8	7	9	14	6	8	0	10 2
C50	Breast		0	0	0	1	4	2	1	1	3	45	48	47	44	32	21	1	9	32

										A	ge Gro	սթ								
I	CD 10 code and site	NK	00-04	02-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+		Total
								8	0	8	2	9	0	8	0	2	1	8		34
C51	Vulva		0	0	1	0	0	0	0 0	9 0	4 0	3	3	0	1	1	1	9 1	0	22
C52	Vagina		0	0	0	0	1	0	2	1	2	3	2	5	9	6	5	2 9	0	45
C53	Cervix uteri		0	0	0	0	1	3	9	3	5	97	14	14	12	12	77	8	2	89
C54	Corpus uteri		0	0	1	0	2	4	5	4 7	9 1	32	2 83	4 95	4 10	1 80	47	2 3	0	5 51
C55	Uterus not specified		0	0	0	0	0	0	3	2	6 9	15	14	27	9 28	16	19	2 1	3	3 15
C56	Ovary																	9		5
			3	1	7	1	1 6	1 3	3 3	2	5 7	94	11 0	12 0	92	10 1	42	5 3	1	78 3
C57	Other and unspecified female genital organs		0	0	0	0	2	0	0	0	2	3	2	8	0	2	2	2	0	23
C58	Placenta		0	0	0	0	2	4	3	2	2	0	0	0	0	0	0	0	0	13
C64	Kidney		8	6	1	0	1	1	2	1	3	10	11	10	16	14	6	5	0	95
C65	Renal pelvis		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C66	Ureter		0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	4
C67	Bladder		0	0	0	0	0	2	0	2	3	6	8	10	17	12	18	2	0	98
C68	Other and unspecified urinary organs		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0 0	0	2
C69	Eye and adnexa		1	1	0	0	0	0	0	0	0	0	0	0	1	3	0	1	0	23
C70	Meninges		7 0	0	0	0	0	0	1	4	1	4	0	1	1	0	1	1	0	14
C71	Brain		4	1	9	7	2	1	1	9	1	19	14	11	15	7	6	4	0	15
C72	Spinal cord, cranial nerves and other parts of central nervous system		1	0 1	0	3	0	0 0	2 0	0	1 1	1	0	0	0	0	0	0	0	0 7
C73	Thyroid gland		0	1	6	4	7 9	9 4	1 5	1	1 3	11 7	91	86	80	43	26	3 9	1	11
C74	Adrenal gland		3	1	0	4	9	4	5 5 5	4	3 9 1	0	2	2	1	0	0	9 0	0	75
C75	Other endocrine glands and related structures		0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2
C76	Other and ill-defined sites		6	0	0	0	0	1	0	4	1	1	3	5	3	3	2	1	2	42
																		1		

										A	ge Gro	ւթ								
I	CD 10 code and site	NK	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+		Total
C80	Unknown primary		1	0	1	0	5	6	6	1	2	33	44	62	70	72	44	5	1	43
C81	Hodgkin disease		0	1	4	0	1	1	5	5 2	2 3	2	4	2	2	3	2	0 0	0	2 59
C82	Follicular (nodular) non- Hodgkin lymphoma		0	0	0	0	0	1	0	4	1	1	3	3	9	3	3	3	0	31
C83	Diffuse non-Hodgkin lymphoma		1	0	2	2	1	4	1	4	2	4	4	6	7	9	5	7	0	59
C84	Peripheral and cutaneous T-cell lymphoma		1	0	1	1	0	1	4	1	2	1	1	0	3	1	2	1	0	20
C85	Other and unspecified types of non-Hodgkin lymphoma		0	1	0	1	3	7	1 0	9	7	7	25	32	24	26	25	2 4	0	20 1
C86	Other lymphoma		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
C88	Immunoproliferative diseases		0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	3
C90	Multiple myeloma and malignant plasma cell neoplasms		0	0	0	0	0	0	0	0	3	6	20	15	27	28	21	2 9	0	14 9
C91	Lymphoid leukaemia		2	1	7	6	6	5	6	2	0	2	4	2	5	9	3	5	0	99
C92	Myeloid leukaemia		5 4	2 3	7	4	5	4	1	9	1	13	18	27	23	17	14	1 9	1	19 2
C93	Monocytic leukaemia		2	0	0	0	0	0	0	0	0	1	0	0	3	3	0	1	0	10
C94	Other leukaemia of specified cell type		1	0	1	0	0	0	1	3	0	2	2	1	1	1	0	0	0	13
C95	Leukaemia of unspecified cell type		2	1	0	1	2	0	0	2	2	1	1	2	3	1	1	1	0	20
C96 D45	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue Polycythaemia vera		8	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
D46	Myelodysplastic syndromes		0	0	0	0	0	0	0	0	0	1	3	1	2	3	6	3	0	3 19
D47	Other neoplasms of uncertain behaviour of lymphoid, haematopoietic and related tissue		0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	2	0	5
	Total		102	56	19	109	167	229	440	603	848	1167	1459	1606	1684	1431	1030	1148	27	12167

Table 7 Number of incidence cancers by five-year age group and site among Males in Sri Lanka, 2013

Cancer Registry	(2013)
General population Sri lan	ka 2013

Cases by age group (Period) - Male

SITE	ALL A		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	56 605 1094 77 168 109 38 220 99	0 0 1 0 0 0 0 0	1	-		1	1 2	34	1 6 11 6 - 1 3 -	2 14 14 7 2 1 1 - 2	36 51 4 12 7 7 2	4 74 116 4 22 9 2 19 6	5 102 146 13 22 18 6 34 23	11 118 174 8 30 20 1 30 13	12 87 154 10 24 24 9 44 12	7 70 153 5 28 12 3 37 16	4 43 121 8 17 14 6 26 10	10 52 147 9 11 3 1 23 14	0.5 5.4 9.8 0.7 1.5 1.0 0.3 2.0 0.9	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	828 391 39 367 468 35 209 71 74	1 0 1 1 0 1 1 0	5		1	1	1	2 2 5 1	5 - 10 2 1 - -	3 6 1 17 9 - 2	37 17 22 20 1 4 6 6	44 29 1 22 30 1 4 7 9	118 51 6 45 30 2 15 11 12	149 72 8 45 60 7 19 10 8	155 71 10 53 82 3 42 13 12	116 56 3 58 60 12 37 8 9	100 39 43 77 3 41 8 5	100 47 4 8 92 4 37 7 11	7.5 3.5 0.4 3.3 4.2 0.3 1.9 0.6 0.7	C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	65 613 1081 53	1 1 2 0	3		-	2		- - 3 9	2 4 5	4 4 8 4	3 15 19 5	1 54 53 4	5 76 110 1	10 96 153 3	14 118 231 9	4 110 214 4	9 65 150 5	7 70 132	0.6 5.5 9.7 0.5	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin	63 48	0	2	3	7	12	9	6	9	4	- 3	2	3	1	1	1	- 8	3 10	0.6	C40-41 C43
Other skin Mesothelioma Kaposi sarcoma Connective and soft tissue	254 6 0 131	1 0 0 0	-	1	1	1	3 - 12	2	2	0 - - 3	17 - 11	18 - 11	27	42	40 1 14	34 - - 8	24 1 10	37	2.3 0.1 0.0 1.2	C44 C45 C46 C47,C49
Breast	64	1	-	-	-	-	-	1	2	3	2	6	7	11	15	7	-	9	0.6	C50
Penis Prostate Testis Other male genital organs	98 717 54 4	0 1 0 0	- 1 1	2	1	1	4	- 8 1	1	3	4 3 4	6 4 7	9 20 2	14 27 1	11 102 2	12 148 1 1	14 184	24 227 2 1	0.9 6.5 0.5 0.0	C60 C61 C62 C63
Kidney Renal pelvis Ureter Bladder Other urinary organs	229 1 5 434 10	0 0 1 0	10 - - -	2	1 - - 1	2		2	7 - 4	8	6 - 12	20 - 12 1	30 1 27	26 1 2 41	40 - 1 88 1	29 - 1 85 6	20 - 75	28 - 83 2	2.1 0.0 0.0 <i>3.9</i> 0.1	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	20 186 265 19 3	0 0 0	8 7 1 8	1 5 1	74	б 1	3 9	3 18	16 27 1	23 35 1	15 29 1	16 17 1	1 20 25 1	2 19 31	3 21 25 2 1	3 13 17 1	6 13 1	1 6 13 1	0.2 1.7 2.4 0.2 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	81 453 3 192	0 0 0	1 13 -	1 9 -	3 7 -	19 1	12 12 -	5 13 - 1	4 14 - 2	9 16 2 2	6 16 - 4	27 15	50 20	7 55 23	5 58 38	3 45 25	3 41 33	58 29	0.7 4.1 0.0 1.7	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	186 218 10 11 27	0 0 0 0	36 5 1	21 5 - 1	23 6 -	17 15 1	9 3 - 1	10 7 -	10 17 2	4 10 - 1 1	3 16 - 1 1	6 14 1	9 18 1 - 2	9 24 - 2 3	6 24 - 1 4	5 24 1 3 3	10 18 2 2 2	8 12 1 1 9	1.7 2.0 0.1 0.1 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified	812	6	5	2	-	2	1	3	11	14	32	71	108	104	124	126	96	107	7.3	0&U
All sites	11364	22	115	55	69	102	91	114	215	253	461	779	1250	1509	1822	1632	1361	1514		ALL
All sites but C44	11110	21	115	55	68	102	88	112	213	247	444	761	1223	1467	1782	1598	1337	1477	100.0	ALLbC44

Table builtThu Dec 31 14:53:10 IST 2020 by CanReg5.

Table 8 Number of incidence cancers by five-year age group and site among Females in Sri

Lanka,2013

Cancer Registry (2013) General population Sri lanka 2013

Cases by age group (Period) - Female

SITE	ALL / AGES U		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	17 137 322 55 16 14 15 47 20	0 0 0 0 0 0 0 0	-		2	1	1 3 - 1	22	5 6 1 - 1	1 5 2 1	1 6 15 6 - 1 1 1	1 12 9 4 1 3 1 4	1 13 25 4 2 3 1 3 1	2 23 29 5 1 1 1 8 5	4 26 59 6 4 3 1 12 3	3 16 47 6 4 - 2 5 1	1 24 48 4 1 2 1 5 4	4 15 77 4 2 2 2 8 5	0.1 1.1 2.7 0.5 0.1 0.1 0.1 0.1 0.4 0.2	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Antis Liver Galibladder etc. Pancreas	676 153 31 440 425 37 84 84 77	0 0 2 1 0 1 0 0	8				1 1 1 - - - 1	1 1 - 3 1 - - 1	4 1 12 10 - 1 - 1	11 - 17 11 2 - 2 2	7 8 34 21 2 4 3 7	24 11 39 31 3 2 11 9	59 16 2 58 44 5 9 16 10	95 23 57 60 7 9 10 12	123 28 5 58 71 2 7 13 12	121 21 7 65 67 7 11 9 14	99 23 2 50 46 4 12 10 3	132 19 3 47 60 4 19 9 5	5.6 1.3 0.3 3.7 3.5 0.3 0.7 0.7 0.7 0.6	C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	35 56 330 26	0 0 1 0	-	1	-	1	1	- 1	3 7 1	3 1 15 1	1 3 14 4	1 29 2	4 5 37 4	4 7 42 1	11 7 53 4	3 6 59 3	2 7 40 2	6 9 31 1	0.3 0.5 2.8 0.2	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin Other skin	62 32 192	1 0 1	2	5	7	8	5	- 3	- 3	7 2 5	3	1 2 9	6 5 19	4 23	4 3 29	2 3 18	1 8 33	2 2 44	0.5 0.3 1.6	C40-41 C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	10 0 109	0000	-	5	- 3	- 8	2	2		1	10	- 9	- 8	2-8	3 - 9	2 14	1 - 6	1	0.1 0.0 0.9	C45 C46 C47,C49
Breast Vulva Vagina Cervix uteri Corpus uteri Uterus unspecified <i>Ovary</i> Other female genital organs Placenta	3234 22 45 895 513 155 783 23 13	9 0 2 0 3 1 0 0			1 	1 - - 14	4 1 1 2 16 2 2	28 3 4 13 4	100 - 2 9 5 3 3 3 3 3 3 3	189 - - - - - 2 26 - - 2	324 2 59 16 9 57 2 2	459 3 97 32 15 94 3	480 3 142 83 14 110 2	478 5 144 95 27 120 8	440 1 9 124 109 28 92 -	322 1 6 121 80 16 101 2	211 5 77 47 19 42 2	189 12 9 82 32 19 53 2	27.0 0.2 0.4 7.5 4.3 1.3 6.5 0.2 0.1	C50 C51 C52 C53 C54 C55 C56 C57 C58
Kidney Renal petvis Ureter Bladder Other urinary organs	95 1 98 2	0 0 0 0	8	6	1	-	1	1	2	1 - - 2 1	3	10 - 6	11 - 8	10 - 1 10	16 1 17	14 - 12 1	6 - 18	5 20	0.8 0.0 0.0 0.8 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	23 171 1175 15 2	0 0 1 0	17 5 3	1 11 1 1	9 6	10 44	2 79	10 94	13 155 5	13 174	13 139 1	24 117	14 91 2 1	12 86 2	1 16 80 1	3 7 43	7 26	1 5 39	0.2 1.4 9.8 0.1 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	59 322 3 149	0 0 0	10 -	1 4 :	4 3 -	4	16 4	13 13	5 15 -	18 1	3 12 - 3	2 13 6	4 33 20	2 41 1 15	43 27	3 39 28	2 35 21	35 1 29	0.5 2.7 0.0 1.2	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	99 215 20 8 19	0 1 0 0 0	25 7 2	12 3 1	7 8 -	6 4 1	6 5 2	5 4 - -	6 13 -	12 2 -	12 2 1	2 16 1 1 1	4 20 1 1 3	28 28 - 1	5 27 3 1 2	9 21 1 - 3	3 14 1 2 6	5 20 1 2 3	0.8 1.8 0.2 0.1 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified	502	3	8	-	1	1	5	8	6	19	26	35	50	73	78	80	46	63	4.2	0&U
All sites All sites but C44	12167 11975	27 26	02 02	56 56	61 61	109 108	167 166	229 226	440 437	603 598	848 845	1167 1158	1459 1440	1606 1583	1684 1655	1431 1413	1030 997	1148 1104	100.0	ALL ALLbC44
and an and the second				2.00					builtThu						a several					

Table 9 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers byfive-year age group and site among Males in Sri Lanka, 2013

							Incide		100,000				• Male										
							inclue	nce per	100,000	i by age	group	(renou)	- male										
SITE	ALL A AGES U		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(00)	UM CU 0-64 0-	M ASE 74	(10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	56 605 1094 77 168 109 38 220 99	0 0 1 0 0 0 0 1	0.1			0.1	0.1 0.3 0.1	0.4 0.5	0.1 0.7 1.4 0.7 0.1 0.4	0.3 2.0 2.0 1.0 0.3 0.1 0.1	5.4 7.6 0.6 1.8 1.0 1.0 0.3	0.6 11.8 18.6 0.6 3.5 1.4 0.3 3.0 1.0	0.9 17.4 24.8 2.2 3.7 3.1 1.0 5.8 3.9	2.2 23.3 34.4 1.6 5.9 3.9 0.2 5.9 2.6	2.8 20.2 35.8 2.3 5.6 5.6 2.1 10.2 2.8	2.4 24.4 53.3 1.7 9.8 4.2 1.0 12.9 5.6	2.2 23.4 65.8 4.4 9.2 7.6 3.3 14.1 5.4	4.4 22.9 64.7 4.0 4.8 1.3 0.4 10.1 6.2	0.6 6.1 11.0 0.8 1.7 1.1 0.4 2.2 1.0	5.4 9.8 0.7 1.5 1.0 0.3 2.0 0.9	0.41 0. 0.63 1. 0.05 0. 0.10 0. 0.08 0. 0.02 0. 0.13 0. 0.05 0.	06 0.9 65 5.9 22 10.1 08 0.7 20 1.0 14 1.0 05 0.4 27 2.1 11 0.9	C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	828 391 39 367 468 35 209 71 74	1 0 1 1 0 1 1 1 0	0.6		0.1	0.1	01	0.3 0.7 0.1	0.6 - 1.2 0.2 0.1 -	0.4 0.9 0.1 2.5 1.3 - 0.3	5.5 2.5 0.1 3.3 3.0 0.1 0.6 0.9 0.9	7.0 4.6 0.2 3.5 4.8 0.2 0.6 1.1 1.4	20.1 8.7 1.0 7.7 5.1 0.3 2.6 1.9 2.0	29.4 14.2 1.6 8.9 11.8 1.4 3.8 2.0 1.6	36.0 16.5 2.3 19.1 0.7 9.8 3.0 2.8	40.4 19.5 1.0 20.2 20.9 4.2 12.9 2.8 3.1	54.4 21.2 22 23.4 41.9 1.6 22.3 4.4 2.7	44.0 20.7 1.8 21.1 40.5 1.8 16.3 3.1 4.8	8.3 3.9 0.4 3.7 4.7 0.4 2.1 0.7	3.5 0.4 3.3 4.2 0.3 1.9 0.6	0.24 0. 0.03 0. 0.20 0. 0.23 0. 0.01 0. 0.09 0. 0.05 0.	97 7.0 44 3.0 04 0.4 55 4.4 04 0.3 27 2.0 08 0.5 07 0.5	C16 C17 C18 C19-20 C21 C22 C23-24
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	65 613 1081 53	1 1 2 0	0.3	0.1	-	0.2	0.4	0.4 1.2	0.2 0.5 0.7 0.6	0.6 0.6 1.2 0.6	0.4 2.2 2.8 0.7	0.2 8.6 8.5 0.6	0.9 12.9 18.7 0.2	2.0 19.0 30.2 0.6	3.3 27.4 53.7 2.1	1.4 38.4 74.6 1.4	4.9 35.4 81.6 2.7	3.1 30.8 58.1	0.7 6.2 10.8 0.5	5.5 9.7 0.5	0.36 0. 0.58 1. 0.04 0.	.07 0.0 73 5.1 36 10.1 .06 0.5	C32 C33-34 C37-38
Bone Melanoma of skin	63 48	0	0.2	0.3	0.8	1.4 0.1	1.2	0.8	1.1	0.6	- 0.4	0.3	0.5	0.2	0.2	0.3	4.4	1.3	0.6			.04 0.0 .06 0.4	
Other skin	254	ĭ	-	-	0.1	-	0.4	0.3	0.2	0.9	2.5	2.9	4.6	8.3	9.3	11.9	13.1	16.3	2.5	2.3	0.15 0.	27 2.3	C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	6 0 131	0 0 0	0.7	0.1	0.7	0.1	1.6	- 0.7	0.1	0.4] 1.6	1.8	1.0	0.2	0.2 3.3	2.8	0.5 5.4	0.4 5.3	0.1 0.0 1.3	0.0	0.00 0.	.01 0.1 .00 0.0 .12 1.3	C46
Breast	64	1	-	-	-	-	-	0.1	0.2	0.4	0.3	1.0	1.2	2.2	3.5	2.4	-	4.0	0.6	0.6	0.05 0.	.06 0.0	
Penis Prostate Testis Other male genital organs	98 717 54 4	0 1 0 0	0.1 0.1 0.1	0.2	0.1	0.1	0.5	- 1.1 0.1	0.1	0.4	0.6 0.4 0.6	1.0 0.6 1.1	1.5 3.4 0.3	2.8 5.3 0.2	2.6 23.7 0.5	4.2 51.6 0.3 0.3	7.6	10.6 100.0 0.9 0.4	1.0 7.2 0.5 0.0	6.5 0.5	0.17 0.	.10 0.9 .93 7.0 .04 0.5 .00 0.0	C61 C62
Kidney Renal pelvis Ureter Bladder Other urinary organs	229 1 5 434 10	0 0 1 0	1.1	0.2	0.1 0.1	0.2	-	0.3	0.9 - 0.5	1.2 0.1	0.9	3.2 1.9 0.2	5.1 0.2 4.6	5.1 0.2 0.4 8.1	9.3 0.2 20.5 0.2	10.1 0.3 29.6 2.1	10.9 	12.3 	2.3 0.0 0.1 4.4 0.1	0.0 0.0 3.9	0.00 0. 0.00 0. 0.19 0.	24 2.1 00 0.0 01 0.0 54 4.1 01 0.1	C65 C66 C67
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	20 186 265 19 3	0 0 0 0	0.9 0.8 0.1 0.9	0.1 0.6 0.1	0.8 0.5 0.1	0.7 0.1	0.4 1.2	0.4 2.4	0.1 2.0 3.4 0.1	3.3 5.0 0.1	2.2 4.3 0.1	2.6 2.7 0.2 0.2	0.2 3.4 4.3 0.2	0.4 3.8 6.1	0.7 4.9 5.8 0.5 0.2	1.0 4.5 5.9 0.3	3.3 7.1 0.5	0.4 2.6 5.7 0.4	0.2 1.9 2.7 0.2 0.0	1.7 2.4 0.2	0.13 0. 0.18 0. 0.01 0.	02 0.1 17 1.3 24 2.4 02 0.1 00 0.0	C70-72 C73 C74
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	81 453 3 192	0 0 0	0.1	0.1	0.4 0.8	1.0 2.3 0.1	1.6 1.6	0.7	0.5	1.3 2.3 0.3 0.3	0.9 2.4 0.6	1.3 4.3 2.4	1.0 8.5 3.4	1.4 10.9 4.5	1.2 13.5 8.8	1.0 15.7 8.7	1.6 22.3 18.0	25.5	0.8 4.5 0.0 1.9	4.1 0.0	0.26 0.	.07 0.8 .45 4.3 .00 0.0 .24 1.8	C82-85,C96 C88
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	186 218 10 <i>11</i> 27	0 0 0 0 0	4.0 0.6 0.1	2.4 0.6 	2.7 0.7	2.1 1.8 0.1	1.2 0.4 - 0.1	1.3 0.9 -	1.2 2.1 0.2	0.6 1.4 0.1 0.1	0.4 2.4 0.1 0.1	1.0 2.2 0.2	1.5 3.1 0.2 0.3	1.8 4.7 0.4 0.6	1.4 5.6 0.2 0.9	1.7 8.4 0.3 1.0 1.0	5.4 9.8 1.1 1.1 1.1	3.5 5.3 0.4 0.4 4.0	1.9 2.2 0.1 0.1 0.3	1.7 2.0 0.1 0.1 0.2	0.11 0. 0.13 0. 0.00 0. 0.00 0. 0.00 0. 0.01 0.	14 2.0 22 2.1 01 0.1 02 0.1 02 0.1	C91 C92-94 C95 MPD MDS
Other and unspecified	812	6	0.6	0.2	-	0.2	0.1	0.4	1.4	2.0	4.8	11.4	18.4	20.5	28.8	43.9	52.2	47.1	8.1			.93 7.0	
All sites	11364	22	12.9	6.2	8.2	12.3	12.1	15.2	26.7	36.5	68.9	124.6	212.7	298.0	423.6	569.0	740.4	666.9	114.0			86 106.5	
All sites but C44	11110	21	12.9	6.2	8.1	12.3	11.7	14.9	26.4	35.6	66.4	121.8	208.1	289.7	414.3	557.1	727.4	650.6	111.5	100.0	a 15 12	59 104 .2	ALLbC44

Cancer Registry (2013) General population Sri lanka 2013

, Reference population: World Standard Population

Table builtFri Dec 11 13:52:43 IST 2020 by CanReg5.

Table 10 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers byfive-year age group and site among Females in Sri Lanka,2013

Cancer Registry (2013)

General population Sri lanka 2013

Incidence per 100,000 by age group (Period) - Female

SITE	ALL / AGES U		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE		CUM C 0-64			ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	17 137 322 55 16 14 15 47 20	0 0 0 0 0 0 0 0 0		-	0.2	0.1 0.1 0.4	0.1	0.2	0.6 0.7 0.1 -	0.1 0.7 0.3 - 0.1	0.1 0.9 2.1 0.9 - - 0.1 0.1 0.1	0.1 1.8 1.3 0.6 0.1 0.4 0.1 0.6	0.2 2.0 3.9 0.6 0.3 0.5 0.2 0.5 0.2	0.4 4.0 5.1 0.9 0.2 0.2 0.2 1.4 0.9	0.8 5.2 11.9 1.2 0.8 0.6 0.2 2.4 0.6	0.8 4.5 13.3 1.7 1.1 - 0.6 1.4 0.3	0.4 10.3 20.6 1.7 0.4 0.9 0.4 2.1 1.7	1.2 4.5 22.9 1.2 0.6 0.6 0.6 2.4 1.5	0.2 1.3 3.0 0.5 0.2 0.1 0.1 0.4 0.4	1.1 2.7 0.5 0.1 0.1 0.1 0.4	0.07 0.13 0.03 0.01 0.01 0.01 0.01 0.03	0.01 0.14 0.30 0.05 0.02 0.01 0.01 0.04 0.02	0.1 1.1 2.5 0.5 0.1 0.1 0.1 0.4 0.1	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	676 153 31 440 425 37 84 84 77	0 0 2 1 0 1 0 0	0.9	0.1	0.1		01 01 01	0.1 0.1 0.4 0.1 -	0.5 0.1 0.1 1.4 1.2 0.1	1.5 2.3 1.5 0.3 0.3 0.3	1.0 1.1 0.4 4.8 3.0 0.3 0.6 0.4 1.0	3.6 0.4 5.8 4.6 0.4 0.3 1.6 1.3	9.1 2.5 0.3 9.0 6.8 1.4 2.5 1.5	16.7 4.0 0.5 10.0 10.5 1.2 1.6 1.8 2.1	24.7 5.6 1.0 11.7 14.3 0.4 1.4 2.6 2.4	34.3 5.9 2.0 18.4 19.0 2.0 3.1 2.5 4.0	42.5 9.9 0.9 21.5 19.7 1.7 5.1 4.3 1.3	39.3 5.7 0.9 14.0 17.9 1.2 5.7 2.7 1.5	6.4 1.4 0.3 4.1 4.0 0.3 0.8 0.8 0.8 0.8	3.7 3.5 0.3 0.7	0.08 0.02 0.23 0.21 0.02 0.03 0.05	0.67 0.16 0.03 0.43 0.41 0.04 0.07 0.08 0.07	5.2 1.2 0.3 3.5 3.3 0.3 0.7 0.7 0.7	C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trache a, bronchus and lung Other thoracic organs	35 56 330 26	0 0 1 0	-	0.1	-	0.1	0.1	0.1	0.4 0.8 0.1	0.4 0.1 2.1 0.1	0.1 0.4 2.0 0.6	0.1 0.9 4.3 0.3	0.6 0.8 5.7 0.6	0.7 1.2 7.4 0.2	2.2 1.4 10.6 0.8	0.8 1.7 16.7 0.8	0.9 3.0 17.2 0.9	1.8 2.7 9.2 0.3	0.3 0.5 3.1 0.2		0.03 0.17 0.02	0.03 0.05 0.34 0.02	0.3 0.4 2.6 0.2	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin Other skin	62 32 192	1	0.2	0.6	0.9	1.0 0.1	0.6	1.0 0.4	0.1	1.0 0.3 0.7	0.1 0.4 0.4	0.1 0.3 1.3	0.9 0.8 2.9	0.2 0.7 4.0	0.8 0.6 5.8	0.6 0.8 5.1	0.4 3.4 14.2	0.6 0.6 13.1	0.6 0.3 1.8	0.3	0.02	0.04 0.04 0.18	0.6 0.3 1.5	C40-41 C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	10 0 109	0 0 0	0.5	0.6	0.4	- 1.0	0.3	0.2	0.8	0.1] 1.4	1.3	1.2	0.4	0.6	0.6 4.0	0.4 2.6	0.3	0.1 0.0 1.0	0.1 0.0 0.9	0.01 0.00 0.06	0.01 0.00 0.09	0.1 0.0 0.9	C45 C46 C47,C49
Breast	3234	9	-	-	-	0.1	0.5	3.4	11.7	25.9	45.9	68.0	74.4	83.9	88.4	91.2	90.5	56.3	30.5	27.0	2.02	2.93	25.8	C50
Vulva Vagina Cervix uteri Corpus uteri Uterus unspecified <i>Ovary</i> Other female genital organs Placenta	22 45 895 513 155 783 23 13	0 0 2 0 3 1 0 0	0.3	0.1	0.1	1.7	0.1 0.1 0.3 2.0 0.3 0.3	0.4 0.5 1.6	0.2 1.1 0.6 0.4 3.9	0.1 4.7 1.0 0.3 3.6	0.3 8.4 2.3 1.3 <i>8.1</i> 0.3 0.3	0.4 0.4 14.4 4.7 2.2 13.9 0.4	0.5 0.3 22.0 12.9 2.2 17.0 0.3	0.9 25.3 16.7 4.7 21.1 1.4	0.2 1.8 24.9 21.9 5.6 18.5	0.3 1.7 34.3 22.6 4.5 28.6 0.6	0.4 2.1 33.0 20.2 8.2 <i>18.0</i> 0.9	3.6 2.7 24.4 9.5 5.7 15.8 0.6	0.2 0.4 8.4 1.5 7.4 0.2 0.1	7.5 4.3 1.3 6.5	0.02 0.51 0.30 0.08 0.46 0.01	0.01 0.04 0.84 0.52 0.15 0.70 0.02 0.01	0.2 0.3 7.0 4.0 1.2 6.3 0.2 0.1	C51 C52 C53 C54 C55 C56 C57 C58
Kidney Renal pelvis Ureter Bladder Other urinary organs	95 1 98 2	0 0 0 0	0.9	0.7	0.1	-	0.1	0.1	0.2	0.1 - 0.3 0.1	0.4 0.4	1.5 0.9	1.7 1.2	1.8 0.2 1.8	3.2 0.2 0.2 3.4	4.0 0.6 3.4 0.3	2.6	1.5 6.0	0.9 0.0 0.0 0.9 0.0	0.0	0.00 0.00 0.04	0.09 0.00 0.00 0.10 0.00	0.8 0.0 0.0 0.8 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	23 171 1175 15 2	0 0 1 0 0	1.9 0.6 0.3	0.1 1.3 0.1 0.1 0.1	1.1 0.7	1.2 5.3	0.3 9.9	1.2 11.5	1.5 18.2 0.6	1.8 23.8	1.8 19.7 0.1	3.6 17.3	2.2 14.1 0.3 0.2	2.1 15.1 0.4	0.2 3.2 16.1 0.2	0.8 2.0 12.2	3.0 11.2	0.3 1.5 11.6	0.2 1.6 11.1 0.1 0.0	1.4 9.8 0.1	0.11 0.76 0.01	0.02 0.13 0.88 0.01 0.00	0.3 1.5 9.8 0.1 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	149	0 0 0	in T	0.1 0.5	0.5	0.5	2.0 0.5	1.6 1.6	0.6	0.3 2.5 0.1	0.4 1.7 0.4	0.3 1.9 0.9	0.6 5.1 3.1	0.4 7.2 0.2 2.6	0.4 8.6 5.4	0.8 11.0 7.9	0.9 15.0 9.0	10.4 0.3 8.6	0.6 3.0 0.0 1.4	2.7 0.0 1.2	0.17 0.00 0.06	0.04 0.30 0.00 0.15	0.5 2.6 0.0 1.1	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloprolifarative disorders Myelodysplastic syndromes	99 215 20 8 19	0 1 0 0 0	2.9 0.8 0.2	1.4 0.3 0.1	0.9	0.7 0.5 0.1	0.8 0.6 0.3	0.6	0.7	0.3 1.6 0.3	1.7 0.3 0.1	0.3 2.4 0.1 0.1 0.1	0.6 3.1 0.2 0.2 0.5	0.4 4.9 0.4	1.0 5.4 0.6 0.2 0.4	2.5 5.9 0.3	1.3 6.0 0.4 0.9 2.6	1.5 6.0 0.3 0.6 0.9	0.9 2.0 0.2 0.1 0.2	1.8 0.2 0.1	0.12 0.01 0.00	0.07 0.18 0.02 0.01 0.02	1.0 1.8 0.2 0.1 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified	502	3	0.9	-	0.1	0.1	0.6	1.0	0.7	2.6	3.7	5.2	7.7	12.8	15.7	22.6	19.7	18.8	4.7	4.2		0.47	4.0	O&U
All sites	12167	27	11.7	6.4	7.4	13.1	20.9	28.0	51.6	82.5	120.2	172.9	226.1	282.0	338.3	405.1	442.0	341.8	114.6		6.82 1		97.6	ALL
All sites but C44	11975	26	11.7	6.4	7.4	13.0	20.8	27.6	51.3	81.8	119.8	171.5	223.2	278.0	332.4	400.0	427.9	328.7		100.0	6,74 1		96.1	ALLbC44
. Reference population: Work	d Standard	Population						Table	builtFri	Dec 111	13:52:43	3 IST 202	20 by Ca	nRee5.										

, Reference population: World Standard Population

Table builtFri Dec 11 13:52:43 IST 2020 by CanReg5.

Table 11 Childhood & Adolescent (0-19) Cancer Incidence Data according to International Childhood Cancer Classification (ICCC-3)

Site	e Group		ICD – O – 3 Histology	Male	Female	Total
Leukemias, myeloproliferative diseases, and myelodyspastic diseases	a. Lymphoid leukaemia	9826	Burkitt cell leukemia	1	0	1
		9835	Precursor cell lymphoblastic leukemia, NOS	61	33	94
		9836	Precursor B-cell lymphoblastic leukemia	26	14	40
		9837	Precursor T-cell lymphoblastic leukemia	9	3	12
	b. Acute myeloid	9840	Acute myeloid leukemia, M6 type	1	0	1
	leukaemia	9861	Acute myeloid leukemia, NOS	6	9	15
		9867	Acute myelomonocytic leukemia	2	1	3
		9872	Acute myeloid leukemia, minimal differentiation	1	0	1
		9873	Acute myeloid leukemia without maturation	1	1	2
		9874	Acute myeloid leukemia with maturation	6	5	11
		9891	Acute monocytic leukemia	6	1	7
		9910	Acute megakaryoblastic leukemia	1	2	3
	c. Chronic myeloproliferative diseases d. Myelodysplastic	9863	Chronic myeloid leukemia, NOS	6	2	8
	syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukemia	1	1	2
		9983	Refractory anemia with excess blasts	1	0	1
	e. Unspecified and other specified leukaemia	9800	Leukemia, NOS	1	2	3
		9801	Acute leukemia, NOS	1	2	3
	Total			131	76	207
Lymphomas and reticuloendothelial	a. Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	7	2	9
neoplasms	Tymphomas	9651	Hodgkin lymphoma, lymphocyte-rich	0	1	1
· · · · · · · · · · · · · · · · · · ·		9652	Hodgkin lymphoma, mixed cellularity, NOS	3	1	4
		9653	Hodgkin lymphoma, lymphocyte depletion, NOS	0	1	1
		9663	Hodgkin lymphoma, nodular sclerosis, NOS	3	0	3

Si	te Group		ICD – O – 3 Histology	Male	Female	Tota
	b. Non-Hodgkin lymphomas(except Burkitt lymphoma)	9591	Malignant lymphoma, non-Hodgkin, NOS	14	2	16
	Durkitt Tymphonia)	9680	Malignant lymphoma, large B-cell, diffuse, NOS	8	2	10
		9690	Follicular lymphoma, NOS	1	0	1
		9699	Marginal zone B-cell lymphoma, NOS	1	0	1
		9702	Mature T-cell lymphoma, NOS	1	0	1
		9714	Anaplastic large cell lymphoma, T cell and	0	3	3
		9727	Precursor cell lymphoblastic lymphoma, NOS	10	2	12
		9729	Precursor T-cell lymphoblastic lymphoma	3	1	4
	c.Burkitt lymphoma	9687	Burkitt lymphoma, NOS	3		3
	d. Miscellaneous lymphoreticular neoplasms	9750	Malignant histiocytosis	0	1	1
	Ĩ	9754	Langerhans cell histiocytosis, disseminated	6	10	16
	e.Unspecified lymphomas	9590	Malignant lymphoma, NOS	2		2
	J 1			2		2
	Total			62	26	88
CNS and miscellaneous intracranial and intraspinal neoplasms	a. Ependymomas and choroid plexus tumour	9390	Choroid plexus carcinoma	1	0	1
· · ·		9391	Ependymoma, NOS	1	4	5
		9392	Ependymoma, anaplastic	1	1	2
	b. Astrocytoma	9380	Glioma, malignant	1	1	2
		9400	Astrocytoma, NOS	3	3	6
		9401	Astrocytoma, anaplastic	0	2	2
		9420	Fibrillary astrocytoma	1	1	2
		9440	Glioblastoma, NOS	3	6	9
	c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	5	3	8
		9471	Desmoplastic nodular medulloblastoma	0	1	1
		9473	Primitive neuroectodermal tumor,	0	5	5

Site	e Group		ICD – O – 3 Histology	Male	Female	Tota
	d. Other gliomas	9380	Glioma, malignant	б	6	12
	u. Other ghomas	9450	Oligodendroglioma, NOS	0	1	12
		1.00		Ū	-	-
	e. Other specified					
	intracranial and	9362	Pineoblastoma		1	1
	intrspinal neoplasms					
	f. Unspecified					
	intrcranial and	8000	Neoplasm, malignant		2	2
	intraspinal neoplasms Total			22	37	59
	Total				57	39
Neuroblastoma						
and other	a. Neuroblastoma and	0.400	Constinueurshipstorus	0	1	1
peripheral nervous cell	ganglioneuroblastom	9490	Ganglioneuroblastoma	0	1	1
tumours						
		9500	Neuroblastoma, NOS	15	5	20
	Total			15	6	21
Retinoblastoma	V. Retinoblastoma	9510	Retinoblastoma, NOS	9	17	26
	Total			9	17	26
	o Norbrohlostoreo					
	a. Nephroblastoma and other	00.00		0	10	01
Renal tumours	nonepithelial renal tumours	8960	Nephroblastoma, NOS	9	12	21
		8963	Malignant rhabdoid tumor	1	0	1
		8964	Clear cell sarcoma of kidney	0	3	3
	B. Renal carcinomas	8260	Papillary adenocarcinoma, NOS	1	0	1
	D. Renai caremonias	8310	Clear cell adenocarcinoma, NOS	1	0	1
		8312	Renal cell carcinoma, NOS	1	0	1
	Total			13	15	28
				_		
Hepatic tumours	a. Hepatoblastoma	8970	Hepatoblastoma	6	9	15
	b. Hepatic	0140			0	
	carcinomas	8140	Adenocarcinoma, NOS	1	0	1
	Total			7	9	16
Malignant bone						
tumours	a. Osteosarcoma	9180	Osteosarcoma, NOS	17	9	26
		9181	Chondroblastic osteosarcoma	1	0	1
	b. Chondrosarcoma	9230	Chondroblastoma, malignant	0	1	1
	o. Chonarosarooma	1230	Chondroonastonia, manghant	U	1	1

Si	te Group		ICD – O – 3 Histology	Male	Female	Tota
	c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	5	10	15
	d. Other specified malignant bone	9250	Giant cell tumor of bone, malignant	1	0	1
	tumours	9370	Chordoma, NOS	1	0	1
	e. Unspecified malignant bone tumours	8000	Neoplasm, malignant	0	1	1
		8800	Sarcoma, NOS	0	1	1
	Total			25	22	47
Soft tissue and other extraosseous sarcoma	a. Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	2	4	б
		8910	Embryonal rhabdomyosarcoma, NOS	4	2	6
		8912	Spindle cell rhabdomyosarcoma	1	0	1
		8920	Alveolar rhabdomyosarcoma	0	1	1
	b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	8811	Fibromyxosarcoma	0	1	1
		9540	Malignant peripheral nerve sheath tumor	3	1	4
		9561	Malig. peripheral nerve sheath tumor, rhabdomyoblastic differentiation	0	1	1
		9580	Granular cell tumor, malignant	0	1	1
	d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumor	3	1	4
		8963	Malignant rhabdoid tumor	0	1	1
		9040	Synovial sarcoma, NOS	2	2	4
		9041	Synovial sarcoma, spindle cell	1	0	1
		9043	Synovial sarcoma, biphasic	1	0	1
		9120	Hemangiosarcoma	1	0	1
		9130	Hemangioendothelioma, malignant	0	1	1
		9252	Malignant tenosynovial giant cell tumor	0	1	1
		9260	Ewing sarcoma	0	1	1
		9364	Peripheral neuroectodermal tumor	1	0	1

Sit	e Group		ICD – O – 3 Histology	Male	Female	Tota
	e. Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	4	1	5
		8801	Spindle cell sarcoma	1	1	2
	Total			24	20	44
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	a. Intracranial and intraspinal germ cell tumours	9080	Teratoma, malignant, NOS	1		1
	b. Malignant extracranial and extragonadal germ cell tumours	9080	Teratoma, malignant, NOS	1	3	4
		9085	Mixed germ cell tumor	0	2	2
	c. Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	4	4
	C	9064	Germinoma	0	2	2
		9071	Yolk sac tumor	2	3	5
		9080	Teratoma, malignant, NOS	1	6	7
		9085	Mixed germ cell tumor	1	2	3
	d. Gonadal carcinoms	8441	Serous cystadenocarcinoma, NOS		1	1
		8460	Papillary serous cystadenocarcinoma		1	1
		8461	Serous surface papillary carcinoma		1	1
		8470	Mucinous cystadenocarcinoma, NOS		2	2
		8480	Mucinous adenocarcinoma		1	1
	e. Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant		2	2
	Total			6	30	36
Other malignant epithelial neoplasms and malignant melanomas	a. Adrenalcortical carcinomas	8370	Adrenal cortical carcinoma	2	1	3
	b. Thyroid carcinomas	8260	Papillary adenocarcinoma, NOS	5	31	36
		8290	Oxyphilic adenocarcinoma	0	1	1
		8330	Follicular adenocarcinoma, NOS	0	6	6

	Site Group		ICD – O – 3 Histology	Male	Female	Tota
		8335	Follicular carcinoma, minimally invasive	0	1	1
		8337	Insular carcinoma	0	1	1
		8340	Papillary carcinoma, follicular variant	1	8	9
		8341	Papillary microcarcinoma	0	2	2
	c. Nasopharyngeal carcinomas	8010	Carcinoma, NOS	1	1	2
	curemonius	8072	Squamous cell carcinoma, large cell, nonkeratin	2	0	2
	d. Malignant melanomas	8720	Malignant melanoma, NOS (except juvenile melanoma)	1	1	2
	e. Skin carcinomas	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
		8402	Nodular hidradenoma, malignant	0	1	1
	f. Other and unspecified carcinomas	8010	Carcinoma, NOS	2	0	2
		8050	Papillary carcinoma, NOS	0	1	1
		8070	Squamous cell carcinoma, NOS	2	1	3
		8130	Papillary transitional cell carcinoma	3	0	3
		8140	Adenocarcinoma, NOS	1	1	2
		8430	Mucoepidermoid carcinoma	0	4	4
		8452	Solid pseudopapillary carcinoma	0	1	1
		8480	Mucinous adenocarcinoma	1	0	1
		8500	Infiltrating duct carcinoma, NOS	0	1	1
	Total			22	63	8
Other and inspecified nalignant ieoplasms	a. Other specified malignant tumours	9050	Mesothelioma, malignant	1		1
	b. Other unspecified malignant tumours	8000	Neoplasm, malignant	3	6	9
		8004	Malignant tumor, spindle cell type	1	1	2
	Total			5	7	12

Mortality of Cancers

Mortality data due to cancers were obtained through the (i) Annual Health Bulletin based on Indoor morbidity mortality return (IMMR) from the hospital statistics and (ii) Department of Census & Statistics website based on data derived from the vital registration system of Sri Lanka.

Year	No. of hospital deaths due to cancers	Crude hospital annual death rate due to cancers per 100,000population	Proportionate Mortality Ratio (PMR) out of all hospital deaths
2005	2753	14.0	8.3
2006	3241	16.3	9.9
2007	3498	17.5	10.1
2008	3485	17.2	9.8
2009	3774	18.5	10.0
2010	4449	21.5	11.1
2011	4631	22.2	11.8
2012	4519	22.2	11.6
2013	4539	22.2	11.2

Table 12 : Deaths due to neoplasms at the government hospitals in Sri Lanka 2005-2013

Sources: Annual Health Bulletin 2005 to 2013.

Table 13 : Deaths due to neoplasms out of all registered deaths (hospital & field) 2001 – 2013 in Sri Lanka

Year	Population		Cancer deaths	
		No.	CR	PMR (%)
2001	18,797,000	8,063	42.9	7.1
2002	18,921,000	7,986	42.2	7.1
2003	19,173,000	8,396	43.8	7.3
2004	19,435,000	9,127	47.0	7.9
2005	19,644,000	9,403	47.9	7.1
2006	19,958,000	10,386	52.3	8.8
2007	20,039,000	10,631	53.1	8.9
2008*				
2009	20,450,000	11,286	55.2	8.8
2010	20,653,000	11,836	57.3	9.1
2011	20,892,000	12,267	58.7	10.0
2012	20,359,439	12,581	61.8	10.2
2013	20,585,041	12,954	62.9	10.2

* Not published

CR-Crude annual death rate due to cancers per 100,000 population

PMR – Proportionate Mortality Ratio out of total deaths

Year		Male			Female	
	No.	CR	ASR	No.	CR	ASR
2001	4375	46.7	52.1	3688	39.1	39.9
2002	4350	46.5	51.2	3636	37.9	38.6
2003	4614	48.7	53.6	3782	38.9	39.6
2004	4942	57.1	57.3	4185	42.9	44.0
2005	4983	50.9	57.0	4420	44.8	45.8
2006	5644	57.1	63.6	4742	47.6	48.7
2007	5827	58.5	65.4	4804	47.6	48.8
2008*						
2009	6105	60.2	67.6	5181	50.3	52.0
2010	6438	62.8	70.9	5398	51.9	53.5
2011	6641	64.0	72.5	5626	53.5	55.3
2012	6908	70.1	65.5	5673	54.0	44.4
2013	7166	71.9	67.4	5788	54.5	44.9


Table 14: Deaths due to cancers out of all registered deaths by sex in hospitals & field in Sri Lanka, 2005 – 2013

Sources: Department of Census & Statistics

* Not published

CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population





Type of Cancer	No	%	CR	ASR
1-034 Malignant neoplasm of trachea, bronchus and lung	902	12.6	9.1	8.5
1-027 Malignant neoplasm of lip, oral cavity and pharynx	863	12.0	8.7	8.1
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	491	6.9	4.9	4.7
1-028 Malignant neoplasm of oesophagus C15	371	5.2	3.7	3.4
1-045 Leukaemia C91-C95	314	4.4	3.2	3.1
1-029 Malignant neoplasm of stomach C16	272	3.8	2.7	2.5
1-042 Malignant neoplasm of meninges, brain and other parts of	251	3.5	2.5	2.4
central nervous system	205	2.0	2.1	1.0
1-030 Malignant neoplasm of colon, rectum and anus C18-C21		2.9		1.9
1-040 Malignant neoplasm of Prostate C61	159	2.2	1.6	1.5
1-043 Non-Hodgkin s lymphoma C82-C85	154	2.1	1.5	1.4
1-026 Neoplasms C00-D48	7166	100.0	71.9	67.4

Table 15 Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2013

Table 16 Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2013

Type of Cancer	No	%	CR	ASR
1-036 Malignant neoplasm of breast	688	11.9	6.5	5.3
1-034 Malignant neoplasm of trachea, bronchus and lung	331	5.7	3.1	2.6
1-038 Malignant neoplasm of other and unspecified parts of uterus	294	5.1	2.8	2.2
1-027 Malignant neoplasm of lip, oral cavity and pharynx	289	5.0	2.7	2.1
1-045 Leukaemia C91-C95	284	4.9	2.7	2.4
1-028 Malignant neoplasm of oesophagus C15	242	4.2	2.3	1.9
1-029 Malignant neoplasm of stomach C16	234	4.0	2.2	1.8
1-042 Malignant neoplasm of meninges , brain and other parts of	220	3.8	2.1	1.8
central nervous system				
1-039 Malignant neoplasm of ovary C56	213	3.7	2.0	1.7
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	207	3.6	1.9	1.6
1-030 Malignant neoplasm of colon, rectum and anus C18-C21	167	2.9	1.6	1.3
1-026 Neoplasms C00-D48	5788	100.0	54.5	44.9



National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka